Dietary Supplement Regulatory Uniformity Act

General monitoring of legislative and administrative action related to health care policy; including the reauthorization of the OTC Monograph Drug User Fee Program (OMUFA); H.R. 1219, Oral Health Products Inclusion Act S.3122 - Better FDA Act of 2025 S.2529 - A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches. S.3677 - Dietary Supplement Listing Act of 2026 H.R. 6868 - ACCESS Through OTC Innovation Act H.R.7366 - Dietary Supplement Regulatory Uniformity Act General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and General monitoring and review of Executive Order 14273, particularly section 9(b) as related to improvements to the process through which prescription drugs can be reclassified as over-the-counter medications, including recommendations to optimally identify prescription drugs that can be safely provided to patients over the counter. Monitoring and review of federal rulemaking processes on Increasing Access to Nonprescription Drugs.

Client expense: $210,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Treasury, Dept of

Monitor the following: H.R.7366, Dietary Supplement Regulatory Uniformity Act, Entirety Essential oils and wellness products related issues and initiatives S.3677, Dietary Supplement Listing Act of 2026, Entirety Cosmetics Regulatory Reform, Implementation related issues HSA/FSA related issues H.R.10336, Dietary Supplement Innovation Act, Entirety

Client expense: Not reported · Firm income: $10,000

Hemp-Derived Cannabidiol (CBD) regulations and legislation Regulatory enforcement of dietary supplements, Mandatory product registration issues H.R.7366, Dietary Supplement Regulatory Uniformity Act, Entirety H.R.7407, Prohibiting Tianeptine and Other Dangerous Products Act of 2026, Entirety H.R.10336, Dietary Supplement Innovation Act, Entirety

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to the prevention of the inclusion of illicit substances like tianeptine in dietary supplements. Mandatory product listing requirements for dietary supplements, including S. 3677 and H.R. 8370, the Dietary Supplement Listing Act of 2026. Issues related to P.L. 103-417, the Dietary Supplement Health and Education Act of 1994 drug preclusion provision, including H.R. 10336, the Dietary Supplement Innovation Act of 2026. Issues related to federal preemption of state requirements applicable to dietary supplements, including H.R. 7366, the Dietary Supplement Regulatory Uniformity Act. Issues related to the generally recognized as safe (GRAS) process. Issues related to FDA's "Simple Reform" reorganization and its impact on dietary supplement facility inspections and specialized inspectional expertise. General issues related to the dietary supplement industry.

Client expense: $70,000 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Ingredients; animal testing; sunscreens; FSA/HSAs covering supplements, mandatory listing of supplements S.355 - FDA Modernization Act 3.0 H.R. 7366 - Dietary Supplement Regulatory Uniformity Act H.R.8370 - Dietary Supplement Listing Act of 2026 S.4587 - Dietary Supplements Access Act/H.R.8933 - Dietary Supplements Access Act

Client expense: $120,000 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE

S.2292 - Over-the-Counter Monograph Drug User Fee Amendments H.R.4273 - Over-the-Counter Monograph Drug User Fee Amendments S.355 - FDA Modernization Act 3.0 H.R.2821 - FDA Modernization Act 3.0 H.R.3686 - SAFE Sunscreen Standards Act H.R.1 - One Big Beautiful Bill Act H.R.5371 - Continuing Appropriations and Extensions Act, 2026 S.2491 - SAFE Sunscreen Standards Act H.R.6868 - ACCESS Through OTC Innovation Act S.2529 - A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches (SMART OTC Act) H.R.6868 - To amend the Federal Food, Drug, and Cosmetic Act to direct the Secretary of Health and Human Services to apply the least burdensome appropriate means for supporting certain administrative order requests with respect to over-the-counter monograph drugs, and for other purposes. S.3122 - Better FDA Act of 2025 H.R.7366 - Dietary Supplement Regulatory Uniformity Act S.3788 - CLEAR LABELS Act - Activity related to Acetaminophen use - Nonprescription Drug Product with an Additional Condition for Nonprescription Use Rule H.R. 10336 - Dietary Supplement Innovation Act

Client expense: Not reported · Firm income: $146,407

Monitor and engage on legislative and administrative action related to health care policy. Monitor and engage on legislative and administrative action related to womens health issues. Monitor and engage on legislative and administrative action related to over-the-counter consumer care products. Monitor and engage on legislative and administrative action related to dietary supplements, including purchasing through HSA funds. Monitor and engage on legislative and administrative action related to servicing of medical device equipment. Monitor and engage on legislative and administrative action related to FDA monograph reform and user fees. Monitor and engage on legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor and engage on legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor and engage on legislative and administrative action related to 340B drug discount program. Monitor and engage on legislative and administrative action related to drug supply chain issues, including pharmacy benefit manager (PBM) reform. Monitor and engage on legislative and administrative action related to copay assistance. Monitor and engage on legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor and engage on legislative and administrative action related to long-acting reversable contraception usage. Monitor and engage on legislative and administrative action related to access to treatments for kidney patients. Monitor and engage on legislative and administrative action related to broader insurance coverage of supplemental imaging procedures for women with dense breast tissue. Monitor and engage on legislative and administrative action related to phenylephrine. Monitor and engage on legislative and administrative action related to e-labeling. Monitor and engage on legislative and administrative action related to DEA-determined pseudoephedrine quotas. Monitor and engage on legislative and administrative action related to Make America Healthy Again (MAHA). Monitor and engage on legislative and administrative action related to generally recognized as safe (GRAS) rules for food additives. H.R. 1262, Give Kids a Chance Act of 2025. H.R. 7366, Dietary Supplement Regulatory Uniformity Act. S. 932, Give Kids a Chance Act of 2025. S. 3677, Dietary Supplement Listing Act of 2026.

H.R.4306 - a bill to amend the Federal Food, Drug, and Cosmetic Act to require the Office of Food Chemical Safety, Dietary Supplements, and Innovation to conduct food chemical safety reassessments, and for other purposes; all provisions related to dietary supplements. H.R. 4968 - a bill to amend the Federal Food, Drug, and Cosmetic Act to require notification to the Food and Drug Administration prior to use of substances as generally recognized as safe, reassessment of the safety of certain substances marketed as generally recognized as safe, provide resources for reviews and reassessments, and for other purposes; all provisions related to dietary supplements S.2341 - A bill to amend the Federal Food, Drug, and Cosmetic Act to impose requirements for substances generally recognized as safe, to require the Commissioner of Food and Drugs to reassess the safety of chemicals added to food, and for other purposes; all provisions related to dietary supplements. H.R. 4958, Grocery Reform and Safety (GRAS) Act (Rep. Pallone), all provisions related to dietary supplements. H.R. 7291, GRAS Oversight and Transparency Act (Rep. Lawler), all provisions related to dietary supplements. H.R. ____, [FDA Review and Evaluation for Safe, Healthy and Affordable Foods Act of 2026] (Rep. Cammack), all provisions related to dietary supplements. H.R. 8370, Dietary Supplement Listing Act of 2026 (Rep. Dexter), all provisions related to dietary supplements. S. 3677, Dietary Supplement Listing Act of 2026 (Sen. Durbin), all provisions related to dietary supplements. H.R. 7366, Dietary Supplement Regulatory Uniformity Act (Rep. Langworthy), all provisions related to dietary supplements. H.R. 8385, Food Labeling Modernization Act of 2026 (Rep. Pallone), all provisions related to dietary supplements. S. 3797, a bill to amend the Federal Food, Drug, and Cosmetic Act to establish new prohibited acts relating to dietary supplements (Sen. Durbin), all provisions related to dietary supplements. H.R. 8933, a bill to amend the Internal Revenue Code of 1986 to include dietary supplements as qualified medical expenses (Rep. LaHood) S. 4587, a bill to amend the Internal Revenue Code of 1986 to include dietary supplements as qualified medical expenses (Sen. Cramer) H.R. 8962, a bill to amend title 10, United States Code, to direct the Secretary of Defense to publish a list of dietary supplement ingredients prohibited for use by members of the Armed Forces, and for other purposes (Rep. Davidson) S. 4626, a bill to amend title 10, United States Code, to direct the Secretary of Defense to publish a list of dietary supplement ingredients prohibited for use by members of the Armed Forces, and for other purposes (Sen. Lee)

Lobbied for the reintroduction of the Dietary Supplement Access Act, which would include dietary supplements as qualified medical expenses eligible for reimbursement under a Health Savings Account. Lobbied in support of H.R. 7366, the Dietary Supplement Regulatory Uniformity Act, legislation to federally preempt state laws on dietary supplement regulation that contravene federal standards.

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to sustainability, animal feed additives, renewable fuels, Generally Recognized as Safe (GRAS) Notification Program, biological products in agriculture, biotechnology and biological products, including the National Biotechnology Initiative Act of 2025 (H.R. 2756/S. 1387), and issues related to dietary supplements including H.R. 7366, the Dietary Supplement Regulatory Uniformity Act. Issues related to nutrition, FDA regulation of feed ingredients, and agricultural biotechnology.

Client expense: $140,000 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE

Monitor and engage on legislative and administrative action related to health care policy. Monitor and engage on legislative and administrative action related to womens health issues. Monitor and engage on legislative and administrative action related to regulation of over-the-counter medicines. Monitor and engage on legislative and administrative action related to dietary supplements, including FDA regulation of ingredients. Monitor and engage on legislative and administrative action related to servicing of medical device equipment. Monitor and engage on legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor and engage on legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor and engage on legislative and administrative action related to 340B drug discount program. Monitor and engage on legislative and administrative action related to drug supply chain issues, including pharmacy benefit manager (PBM) reform. Monitor and engage on legislative and administrative action related to copay assistance. Monitor and engage on legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor and engage on legislative and administrative action related to access to treatments for kidney patients. Monitor and engage on legislative and administrative action related to Make America Healthy Again (MAHA). Monitor and engage on legislative and administrative action related to generally recognized as safe (GRAS) rules for food additives. Monitor and engage on legislative and administrative action related to FDA regulation of cell and gene therapies. Monitor and engage on legislative and administrative action related to Parkinsons disease. Monitor and engage on legislative and administrative action related to federal investment in biotech development and manufacturing. H.R. 6118, Support and Defend Our Military Personnel and Their Families Act. H.R. 7366, Dietary Supplement Regulatory Uniformity Act. S. 3677, Dietary Supplement Listing Act of 2026. S. 3788, CLEAR Labels Act.

Issues pertaining to food and nutrition policies Discussions involving federal preemption Discussions involving front-of-pack labeling Monitored H.R. 4958, the Grocery Reform and Safety (GRAS) Act Monitored H.R. 7291, the GRAS Oversight and Transparency Act Monitored H.R. ____, the FDA Review and Evaluation for Safe, Healthy and Affordable Foods (FRESH) Act of 2026 Monitored H.R. 4306, the Food Chemical Reassessment Act of 2025 Monitored H.R. 8385, the Food Labeling Modernization Act of 2026 Monitored H.R. 8429, the Baby Food Safety Act of 2026 Monitored H.R. 7867, the Infant Formula Safety Modernization Act of 2026 Monitored H.R. 4725, the Transparency, Readability, Understandability, Truth, and Helpfulness (TRUTH) in Labeling Act Monitored H.R. 2472, the Improving Newborns' Food and Nutrition Testing Safety (INFANTS) Act of 2025 Monitored H.R. 2511, the Sarah Katz Caffeine Safety Act Monitored H.R. 5882, the No Tricks on Treat Act of 2025 Monitored H.R. 8370, the Dietary Supplement Listing Act of 2026 Monitored H.R. 8430, the Federal and State Food Safety Information Sharing Act Monitored H.R. 3722, the Do or Dye Act Monitored H.R. 5027, the Ban Harmful Food Dyes Act Monitored H.R. 1394, the Codifying Useful Regulatory Definitions (CURD) Act Monitored H.R. 1178, the Alpha-gal Allergen Inclusion Act Monitored H.R. 2162, the Honey Integrity Act Monitored H.R. 4987, the Food Date Labeling Act of 2025 Monitored H.R. 5832, the Requiring Ethical and Accurate Labeling of Lab-grown (REAL) Meats Act Monitored H.R. 7366, the Dietary Supplement Regulatory Uniformity Act Monitored H.R. 2615, the Stephen Hacala Poppy Seed Safety Act Monitored H.R. 3324, the Safer Shrimp Imports Act Monitored H.R. 933, the Defending Domestic Orange Juice Production Act of 2025 Monitored H.R. 8414, the DAIRY PRIDE Act Monitored H.R. 8431, the Third-Party Certification and Inspection Modernization Act of 2026 Monitored H.R. 8412, the No False Formula Act Monitored H.R. 8432, the To Provide the FDA Needed Authorities for Human Foods

General monitoring of legislative and administrative action related to health care policy; including the reauthorization of the OTC Monograph Drug User Fee Program (OMUFA); S.3122 - Better FDA Act of 2025 S.2529 - A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches. S.3677 - Dietary Supplement Listing Act of 2026 H.R. 6868 - ACCESS Through OTC Innovation Act H.R.7366 - Dietary Supplement Regulatory Uniformity Act General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and General monitoring and review of Executive Order 14273, particularly section 9(b) as related to improvements to the process through which prescription drugs can be reclassified as over-the-counter medications, including recommendations to optimally identify prescription drugs that can be safely provided to patients over the counter. Monitoring and review of federal rulemaking processes on Increasing Access to Nonprescription Drugs.

Ingredients; animal testing; sunscreens; FSA/HSAs covering supplements, mandatory listing of supplements S.355 - FDA Modernization Act 3.0 H.R. 7366 - Dietary Supplement Regulatory Uniformity Act H.R.8370 - Dietary Supplement Listing Act of 2026 S.4587 - Dietary Supplements Access Act/H.R.8933 - Dietary Supplements Access Act

Client expense: $130,000 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE

Issues related to the prevention of the inclusion of illicit substances like tianeptine in dietary supplements. Mandatory product listing requirements for dietary supplements, including S. 3677 and H.R. 8370, the Dietary Supplement Listing Act of 2026. Issues related to P.L. 103-417, the Dietary Supplement Health and Education Act of 1994 drug preclusion provision. Issues related to federal preemption of state requirements applicable to dietary supplements, including H.R. 7366, the Dietary Supplement Regulatory Uniformity Act. Issues related to the generally recognized as safe (GRAS) process. General issues related to the dietary supplement industry.

Client expense: $100,000 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Monitor the following: H.R.7366, Dietary Supplement Regulatory Uniformity Act, Entirety Essential oils and wellness products related issues and initiatives S.3677, Dietary Supplement Listing Act of 2026, Entirety Cosmetics Regulatory Reform, Implementation related issues HSA/FSA related issues

Client expense: Not reported · Firm income: $20,000

Hemp-Derived Cannabidiol (CBD) regulations and legislation Regulatory enforcement of dietary supplements, Mandatory product registration issues H.R.7366, Dietary Supplement Regulatory Uniformity Act, Entirety H.R.7407, Prohibiting Tianeptine and Other Dangerous Products Act of 2026, Entirety

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S.2292 - Over-the-Counter Monograph Drug User Fee Amendments H.R.4273 - Over-the-Counter Monograph Drug User Fee Amendments S.355 - FDA Modernization Act 3.0 H.R.2821 - FDA Modernization Act 3.0 H.R.3686 - SAFE Sunscreen Standards Act H.R.1 - One Big Beautiful Bill Act H.R.5371 - Continuing Appropriations and Extensions Act, 2026 S.2491 - SAFE Sunscreen Standards Act S.2529 - A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches (SMART OTC Act) H.R.6868 - To amend the Federal Food, Drug, and Cosmetic Act to direct the Secretary of Health and Human Services to apply the least burdensome appropriate means for supporting certain administrative order requests with respect to over-the-counter monograph drugs, and for other purposes. S.3122 - Better FDA Act of 2025 H.R.7366 - Dietary Supplement Regulatory Uniformity Act S.3788 - CLEAR LABELS Act - Activity related to Acetaminophen use - Nonprescription Drug Product with an Additional Condition for Nonprescription Use Rule - Dietary Supplement Drug Preclusion - legislation intended to clarify ingredients that can be used in dietary supplements.

Client expense: Not reported · Firm income: $199,750

H.R.4306 - a bill to amend the Federal Food, Drug, and Cosmetic Act to require the Office of Food Chemical Safety, Dietary Supplements, and Innovation to conduct food chemical safety reassessments, and for other purposes; all provisions related to dietary supplements. H.R. 4968 - a bill to amend the Federal Food, Drug, and Cosmetic Act to require notification to the Food and Drug Administration prior to use of substances as generally recognized as safe, reassessment of the safety of certain substances marketed as generally recognized as safe, provide resources for reviews and reassessments, and for other purposes; all provisions related to dietary supplements S.2341 - A bill to amend the Federal Food, Drug, and Cosmetic Act to impose requirements for substances generally recognized as safe, to require the Commissioner of Food and Drugs to reassess the safety of chemicals added to food, and for other purposes; all provisions related to dietary supplements. H.R. 4958, Grocery Reform and Safety (GRAS) Act (Rep. Pallone), all provisions related to dietary supplements. H.R. 7291, GRAS Oversight and Transparency Act (Rep. Lawler), all provisions related to dietary supplements. H.R. ____, [FDA Review and Evaluation for Safe, Healthy and Affordable Foods Act of 2026] (Rep. Cammack), all provisions related to dietary supplements. H.R. 8370, Dietary Supplement Listing Act of 2026 (Rep. Dexter), all provisions related to dietary supplements. S. 3677, Dietary Supplement Listing Act of 2026 (Sen. Durbin), all provisions related to dietary supplements. H.R. 7366, Dietary Supplement Regulatory Uniformity Act (Rep. Langworthy), all provisions related to dietary supplements. H.R. 8385, Food Labeling Modernization Act of 2026 (Rep. Pallone), all provisions related to dietary supplements. S. 3797, a bill to amend the Federal Food, Drug, and Cosmetic Act to establish new prohibited acts relating to dietary supplements (Sen. Durbin), all provisions related to dietary supplements.

Monitor and engage on legislative and administrative action related to health care policy. Monitor and engage on legislative and administrative action related to womens health issues. Monitor and engage on legislative and administrative action related to over-the-counter consumer care products. Monitor and engage on legislative and administrative action related to dietary supplements, including purchasing through HSA funds. Monitor and engage on legislative and administrative action related to servicing of medical device equipment. Monitor and engage on legislative and administrative action related to FDA monograph reform and user fees. Monitor and engage on legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor and engage on legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor and engage on legislative and administrative action related to 340B drug discount program. Monitor and engage on legislative and administrative action related to drug supply chain issues, including pharmacy benefit manager (PBM) reform. Monitor and engage on legislative and administrative action related to copay assistance. Monitor and engage on legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor and engage on legislative and administrative action related to long-acting reversable contraception usage. Monitor and engage on legislative and administrative action related to access to treatments for kidney patients. Monitor and engage on legislative and administrative action related to broader insurance coverage of supplemental imaging procedures for women with dense breast tissue. Monitor and engage on legislative and administrative action related to phenylephrine. Monitor and engage on legislative and administrative action related to e-labeling. Monitor and engage on legislative and administrative action related to DEA-determined pseudoephedrine quotas. Monitor and engage on legislative and administrative action related to Make America Healthy Again (MAHA). Monitor and engage on legislative and administrative action related to generally recognized as safe (GRAS) rules for food additives. H.R. 1262, Give Kids a Chance Act of 2025. H.R. 7366, Dietary Supplement Regulatory Uniformity Act. S. 932, Give Kids a Chance Act of 2025. S. 3677, Dietary Supplement Listing Act of 2026.

Issues related to sustainability - no specific legislation. Issues related to animal feed additives, sustainability, renewable fuels, Generally Recognized as Safe (GRAS) Notification Program, and biological product in agriculture - no specific legislation. Issues related to biotechnology and biological products including H.R.2756/S.1387 - National Biotechnology Initiative Act of 2025. H.R. 7366 - Dietary Supplement Regulatory Uniformity Act - Issues related to dietary supplements.

Client expense: $220,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to the prevention of the inclusion of illicit substances like tianeptine in dietary supplements. Issues related to P.L. 103-417, the Dietary Supplement Health and Education Act of 1994 drug preclusion provision. Mandatory product listing requirements for dietary supplements, including policy issues related to S. 3677, the Dietary Supplement Listing Act of 2026. Issues related to federal preemption of state requirements applicable to dietary supplements, including H.R. 7366, the Dietary Supplement Regulatory Uniformity Act. General issues related to the dietary supplement industry.

Client expense: $70,000 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R.7366, Dietary Supplement Regulatory Uniformity Act, Entirety Monitor the following: Essential oils and wellness products related issues and initiatives S.3677, Dietary Supplement Listing Act of 2026, Entirety Cosmetics Regulatory Reform, Implementation related issues HSA/FSA related issues

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES

Hemp-Derived Cannabidiol (CBD) regulations and legislation Regulatory enforcement of dietary supplements, Mandatory product registration issues H.R.7366, Dietary Supplement Regulatory Uniformity Act, Entirety

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Lobbied for the reintroduction of the Dietary Supplement Access Act, which would include dietary supplements as qualified medical expenses eligible for reimbursement under a Health Savings Account. Lobbied in support of H.R. 7366, the Dietary Supplement Regulatory Uniformity Act, legislation to federally preempt state laws on dietary supplement regulation that contravene federal standards.

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S.2292 - Over-the-Counter Monograph Drug User Fee Amendments H.R.4273 - Over-the-Counter Monograph Drug User Fee Amendments S.355 - FDA Modernization Act 3.0 H.R.2821 - FDA Modernization Act 3.0 H.R.3686 - SAFE Sunscreen Standards Act H.R.1 - One Big Beautiful Bill Act H.R.5371 - Continuing Appropriations and Extensions Act, 2026 S.2491 - SAFE Sunscreen Standards Act S.2529 - A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches (SMART OTC Act) H.R.6868 - To amend the Federal Food, Drug, and Cosmetic Act to direct the Secretary of Health and Human Services to apply the least burdensome appropriate means for supporting certain administrative order requests with respect to over-the-counter monograph drugs, and for other purposes. S.3122 - Better FDA Act of 2025 H.R.7366 - Dietary Supplement Regulatory Uniformity Act - Activity related to Acetaminophen use - Nonprescription Drug Product with an Additional Condition for Nonprescription Use Rule - Dietary Supplement Drug Preclusion - legislation intended to clarify ingredients that can be used in dietary supplements.

Client expense: Not reported · Firm income: $159,409